相关实验视频

Updated: Jan 15, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

新诊断FLT3-内部并列重复-阴性AML的奎萨丁尼布:随机,双盲,安慰剂控制,II期QUIWI研究

Pau Montesinos¹, Rebeca Rodríguez-Veiga¹, Juan Miguel Bergua²

¹Hospital Universitari I Politécnic La Fe, Valencia, Spain.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

|October 13, 2025

概括

在新诊断的FLT3-ITD阴性AML患者中,Quizartinib在添加到标准化疗时显著改善了无事件生存率和整体生存率. 这种组合疗法为这个患者群体提供了一个有前途的新治疗方案.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

奎萨丁尼布是一种选择性II型FLT3抑制剂.
之前的试验显示在复发/耐药AML中有效.
量子第一试验证明了FLT3-ITD阳性AML患者的生存益处.

研究的目的:

评估quizartinib在新诊断的FLT3-ITD阴性AML.患者中的安全性和有效性.
为了比较quizartinib加标准化疗与安慰剂加标准化疗.

主要方法:

第二阶段,随机,双盲,安慰剂控制的QUIWI试验.
18-70岁的新诊断的FLT3-ITD阴性AML患者.
奎萨丁尼布或安慰剂添加到标准的诱导,巩固和维持化疗中.

主要成果:

奇萨丁尼布的无事件生存时间中位数为20.4个月,而安慰剂为9.9个月 (P=.046).
基萨丁尼布的中位数整体存活期未达到,与安慰剂相比为29.3个月 (P=.012).
三年后的OS率为60.8% (奎扎尔提尼布) 和45.7% (安慰剂).

结论:

在标准化疗中添加quizartinib,可显著改善新诊断的FLT3-ITD阴性AML的EFS和OS.
奎萨丁尼布在这个患者群体中表现出有利的安全性.
这种疗法代表了对FLT3-ITD阴性AML的潜在新标准护理.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...